Reduced Glutathione [Nasal Spray]

Description

What is Reduced Glutathione (GSH) Nasal Spray?

Glutathione (GSH; gamma-glutamylcysteinylglycine; L-gamma-glutamyl-L-cysteinyl-glycine) is a low-molecular-weight endogenous tripeptide thiol found in virtually all mammalian cells, with intracellular concentrations ranging from 0.5 to 10 millimolar, making it the most abundant non-protein thiol in animal tissues. It is synthesized intracellularly from three amino acids, L-glutamate, L-cysteine, and glycine, in a sequential two-step enzymatic process catalyzed by gamma-glutamylcysteine synthetase (glutamate-cysteine ligase; GCL) and glutathione synthetase (GS). The gamma-peptide bond connecting glutamate to cysteine in GSH is structurally distinctive: it forms via the gamma-carboxyl group of glutamate rather than the alpha-carboxyl group, making GSH resistant to the aminopeptidases that cleave conventional alpha-peptide bonds and conferring it with a unique structural stability absent in standard linear peptides. Reduced glutathione (GSH) and its oxidized disulfide form (GSSG) constitute the primary redox couple in mammalian cells; the GSH/GSSG ratio is a key indicator of cellular redox status and oxidative stress [Wu et al., 2004; PMID 14988435].

Glutathione serves as both a direct antioxidant and a critical co-substrate for enzymatic antioxidant defense. As a direct antioxidant, the free sulfhydryl (-SH) group of the cysteine residue donates electrons to neutralize reactive oxygen species (ROS) and reactive nitrogen species (RNS), becoming oxidized to GSSG in the process. As a co-substrate, GSH serves as an essential electron donor to the glutathione peroxidase (GPx) enzyme family, catalyzing the reduction of hydrogen peroxide and lipid hydroperoxides; as a nucleophilic co-substrate to the glutathione-S-transferase (GST) superfamily, facilitating detoxification of electrophilic xenobiotics; and as a substrate for glutaredoxins in the reversible reduction of protein disulfide bonds. GSH deficiency has been documented across a broad range of pathological conditions, including neurodegenerative diseases, Alzheimer’s disease, HIV/AIDS, cancer, liver disease, and diabetes [Franco et al., 2007; PMID 18158646].

Reduced glutathione supplied by RCDbio has not been approved as a standalone pharmaceutical product by the FDA for human use via the intranasal route. The research-grade nasal spray formulation is not a pharmaceutical or compounded medication, is not a dietary supplement, and is not equivalent to any approved glutathione-containing product. The intranasal route is of particular research interest for glutathione because of its poor oral bioavailability (due to degradation by gamma-glutamyl transpeptidase in the GI mucosa) and the established evidence that intranasal administration can elevate brain GSH levels [Mischley et al., 2015; PMID 26230671].

The nasal spray formulation is investigated as a delivery route in preclinical research contexts, based on evidence of olfactory bulb-mediated CNS transport for compounds administered intranasally in rodent models and direct Phase I/IIa clinical evidence of safety and tolerability of intranasal glutathione in human subjects with Parkinson’s disease [Mischley et al., 2015; PMID 26230671]. Intranasal delivery has been studied for its potential to bypass hepatic first-pass metabolism, circumvent GI-tract gamma-glutamyl transpeptidase-mediated degradation, and enhance CNS bioavailability relative to oral and systemic routes.

DISCLAIMER: Reduced Glutathione (GSH) Nasal Spray as supplied by RCDbio is not a dietary supplement and has not been approved by the Food and Drug Administration for human use, veterinary use, consumption, or any therapeutic application via the intranasal route. This product is not intended for human consumption or therapeutic self-administration. It is supplied exclusively for in vitro and preclinical laboratory research purposes. All RCDbio research compounds are for laboratory and research purposes only.

Chemical Properties of Reduced Glutathione (GSH)

How Does Reduced Glutathione (GSH) Work?

Reduced glutathione (GSH) does not act through a single receptor. Instead, it functions as a multifunctional intracellular molecule whose activity depends on the free sulfhydryl (-SH) group on its cysteine residue. This group enables direct electron donation and supports multiple enzyme systems. GSH participates in antioxidant defense, detoxification, protein thiol regulation, and redox-sensitive signaling pathways. The mechanisms described below are based on in vitro and preclinical evidence unless otherwise noted.

Direct Antioxidant Activity and the GSH/GSSG Redox Cycle

The sulfhydryl group of GSH directly neutralizes reactive oxygen species (ROS) and reactive nitrogen species (RNS), including superoxide radicals, hydrogen peroxide, and hydroxyl radicals. During this process, two GSH molecules are oxidized to glutathione disulfide (GSSG). Glutathione reductase (GR) then regenerates GSH using NADPH as the electron donor, maintaining the cellular redox cycle. Under normal conditions, mammalian cells maintain a GSH/GSSG ratio above 100:1, while oxidative stress shifts this balance toward GSSG accumulation [Wu et al., 2004; PMID 14988435].

Role as a Co-substrate for Glutathione Peroxidase (GPx)

GSH serves as the essential electron donor for the glutathione peroxidase (GPx) enzyme family. These enzymes reduce hydrogen peroxide and lipid hydroperoxides into less reactive products while converting GSH into GSSG. GPx1, GPx4, and GPx8 all depend on sufficient intracellular GSH. Reduced GSH availability can impair GPx activity and promote hydrogen peroxide accumulation, lipid peroxidation, mitochondrial dysfunction, and ferroptosis-related pathways [Franco et al., 2007; PMID 18158646].

Glutathione-S-Transferase (GST) and Detoxification Pathways

GSH acts as a required co-substrate for the glutathione-S-transferase (GST) enzyme family. GST enzymes conjugate glutathione to electrophilic xenobiotics, carcinogens, and reactive metabolites, making them easier to eliminate from the body. This reaction is a major component of phase II detoxification and helps neutralize reactive products generated during cytochrome P450 metabolism [Franco et al., 2007; PMID 18158646].

Protein S-Glutathionylation and Cellular Redox Signaling

During oxidative stress, GSH reversibly modifies protein cysteine residues through S-glutathionylation. This post-translational modification protects protein thiols from irreversible oxidation while regulating proteins involved in signal transduction, gene expression, apoptosis, and cell proliferation. GSH also influences redox-sensitive pathways such as NF-κB, AP-1, and Nrf2, contributing to antioxidant responses and inflammatory regulation [Franco et al., 2007; PMID 18158646].

Intranasal Research and Central Nervous System Redox Studies

Reduced glutathione depletion within the substantia nigra is considered one of the earliest neurochemical changes observed in Parkinson’s disease. In a Phase I/IIa clinical trial, 30 participants received placebo, 300 mg/day, or 600 mg/day intranasal glutathione for three months. Adverse events were similar across groups, and all treatment arms met tolerability criteria, supporting the safety and tolerability of intranasal administration. These findings relate only to safety and tolerability and should not be interpreted as evidence of efficacy [Mischley et al., 2015; PMID 26230671].

Intranasal Delivery and Pharmacokinetic Considerations

Nose-to-Brain Transport and Avoidance of Gastrointestinal Degradation

Orally administered glutathione undergoes extracellular degradation by gamma-glutamyl transpeptidase (GGT) in the intestinal brush border, limiting systemic availability. Intranasal delivery bypasses gastrointestinal degradation and first-pass hepatic metabolism. With a molecular weight of approximately 307 Da, GSH is well-suited for nasal absorption. Clinical research in Parkinson’s disease has demonstrated acceptable safety and tolerability of intranasal administration, while preclinical studies have characterized olfactory and trigeminal pathways involved in nose-to-brain transport [Mischley et al., 2015; PMID 26230671; Wong et al., 2024; PMID 38441832].

Maintaining the Reduced Form During Formulation

Unlike many research compounds, glutathione depends on preservation of its reduced thiol form (GSH) for biological activity. In aqueous solutions, oxidation to GSSG can occur rapidly in the presence of oxygen, particularly at neutral or alkaline pH and when trace metal ions are present. Research formulations are commonly prepared in nitrogen-purged isotonic saline at pH 5.0–6.5 to minimize oxidation. Because each spray introduces air exposure, researchers should minimize repeated opening cycles and verify reduced-form integrity with Ellman’s reagent before conducting redox-sensitive experiments.

Nasal Absorption Characteristics

With a molecular weight of 307.32 g/mol (approximately 0.31 kDa), GSH is among the smallest molecules commonly investigated for intranasal research. Its size supports efficient movement across the nasal mucosa. However, because GSH is hydrophilic, paracellular transport is expected to contribute more than passive transcellular diffusion. Interaction with membrane-bound GGT at the nasal surface may also influence the amount of intact GSH absorbed.

Current Evidence for Intranasal Pharmacokinetics

As of June 2026, no published studies have established formal pharmacokinetic parameters such as Tmax, Cmax, or brain bioavailability for research-grade intranasal reduced glutathione. The available Phase I/IIa clinical study focused on safety and tolerability rather than pharmacokinetics [Mischley et al., 2015; PMID 26230671]. Researchers should also consider potential nasal GGT-mediated degradation and the compound’s susceptibility to oxidation when designing experimental protocols.

Key Research Findings

GSH Biosynthesis and Functions in Cellular Redox Biology: Glutathione (GSH) synthesis is regulated primarily by gamma-glutamylcysteine synthetase activity and the availability of cysteine. The GSH/GSSG pair represents the principal intracellular redox system in animal cells. Beyond antioxidant defense, GSH contributes to nutrient metabolism, gene expression, DNA synthesis, cell proliferation, apoptosis, signal transduction, cytokine production, and immune function. Reduced GSH levels have been associated with oxidative stress during aging and with the pathophysiology of conditions including Parkinson’s disease, Alzheimer’s disease, liver disease, HIV/AIDS, and cancer [Wu et al., 2004; PMID 14988435].

GSH in Antioxidant Defense, Detoxification, and Cellular Signaling: GSH metabolism and transport play central roles in antioxidant protection, xenobiotic detoxification, and redox-sensitive signaling pathways. GSH also participates in the regulation of gene expression, apoptosis, and cell proliferation. Altered glutathione homeostasis has been reported in disorders such as diabetes, cancer, HIV/AIDS, neurodegenerative diseases, and liver disease. In addition, GSH catabolism influences multiple redox-dependent signaling cascades [Franco et al., 2007; PMID 18158646].

Phase I/IIa Clinical Study of Intranasal Glutathione in Parkinson’s Disease: A randomized, double-blind Phase I/IIa trial evaluated intranasal glutathione in 30 participants with Parkinson’s disease. Subjects received placebo, 300 mg/day, or 600 mg/day in three divided daily doses for three months. No substantial differences in adverse events or safety measures were observed between groups, and all treatment arms met predefined tolerability criteria. These findings support the safety and tolerability of intranasal glutathione under the studied conditions [Mischley et al., 2015; PMID 26230671].

Research Context and Interpretation

The first two references summarize mechanistic reviews describing glutathione biology in cellular and animal research models. The third reference is the only published Phase I/IIa randomized, double-blind clinical study investigating intranasal glutathione and focuses on safety and tolerability in individuals with Parkinson’s disease. It does not establish efficacy for any therapeutic indication.

Within the RCDbio nasal spray research portfolio, reduced glutathione is the only compound with published human Phase I/IIa data evaluating intranasal administration. These findings apply only to the specific clinical population and study conditions investigated and should not be interpreted as evidence of efficacy or safety for the research-grade nasal spray formulation in other organisms or experimental settings.

What are the Potential Research Applications?

In controlled laboratory settings, reduced glutathione nasal spray has been investigated across several areas of preclinical and in vitro research. Unless otherwise stated, the applications described below are based on experimental models and should not be interpreted as evidence of efficacy or safety in any organism.

Central Nervous System Oxidative Stress Research

The intranasal route has been explored as an approach for studying oxidative stress within the central nervous system (CNS). Human clinical data support the safety and tolerability of intranasal glutathione under the conditions studied [Mischley et al., 2015; PMID 26230671].

Research applications include measuring brain glutathione levels after intranasal administration in rodent models, investigating glutathione depletion and supplementation in neurodegenerative disease models, evaluating oxidative stress within the substantia nigra, characterizing hippocampal redox status, and comparing intranasal with systemic glutathione delivery.

Cellular Redox Biology and GSH/GSSG Research

GSH serves as the primary intracellular redox buffer and is widely used in studies of cellular redox homeostasis.

Research applications include determining GSH/GSSG ratios under different oxidative stress conditions, evaluating glutathione peroxidase (GPx) activity, investigating glutaredoxin-mediated protein deglutathionylation, examining NF-κB and Nrf2 signaling pathways, and studying ferroptosis-related mechanisms through the GPx4/GSH axis.

Detoxification and Phase II Metabolism Studies

Glutathione is commonly investigated for its role in cellular detoxification pathways and Phase II metabolism.

Research applications include characterizing glutathione-S-transferase (GST) isoenzyme substrate specificity, mapping electrophile detoxification pathways in hepatocyte preparations, evaluating drug–glutathione conjugation reactions, and studying chemotherapy resistance mechanisms associated with GST/GSH signaling.

Intranasal Pharmacokinetics and Delivery Research

With a molecular weight of approximately 307 Da, high water solubility, and published human safety data for intranasal administration, GSH is frequently used as a model compound in delivery research.

Research applications include characterizing nose-to-brain transport of small hydrophilic thiol molecules in rodent olfactory models, optimizing intranasal formulations, and comparing CNS bioavailability following intranasal, systemic, and oral glutathione administration.

What are the Potential Side Effects?

Researchers in preclinical and in vitro settings have noted the following observations. Long-term safety and toxicity profiles remain incompletely characterized for the research-grade nasal spray formulation.

Favorable clinical safety and tolerability — established in Phase I/IIa intranasal clinical data: Intranasal glutathione at 300-600 mg/day for 3 months was safe and well-tolerated in 30 PD patients with no substantial differences in adverse events between treatment and placebo groups [Mischley et al., 2015; PMID 26230671]; this constitutes human-specific intranasal safety data but does not establish safety for the research-grade formulation outside the specific clinical context

• Nasal mucosal irritation (local administration context): Sinus irritation and hyposmia were monitored as safety endpoints in the Phase I/IIa trial; mild nasal irritation or epistaxis is a possible local reaction at high concentrations
• Oxidized GSSG content — stability-related consideration: If the formulation has been used past the 7-day in-use shelf life or the reduced form has been compromised, GSSG may be present; confirm reduced form by Ellman’s reagent before use in sensitive cell preparations
• Sulfhydryl-related reactivity (high concentration context): At high concentrations, the free thiol group of GSH may react with oxidized protein cysteines in cell-free assay systems; this is a relevant confound in protein biochemistry assay systems
• No established safety concerns at physiological concentrations: As an endogenous metabolite present in all mammalian cells at millimolar concentrations, GSH has no reported acute toxicity at physiological and near-physiological concentrations

No human safety or tolerability data has been established for the research-grade reduced glutathione nasal spray formulation. These observations are derived from the clinical context (Mischley et al., 2015) and experimental systems and should not be extrapolated to outcomes outside the specific populations and protocols studied.

Risk & Handling

Handling Precautions

Standard laboratory PPE is required: nitrile gloves, a laboratory coat, and eye protection. The following nasal spray-specific and compound-specific precautions apply:

1. Do not direct the nasal spray actuator toward the face, eyes, or mucous membranes during handling, testing, or transfer. Although glutathione is an endogenous metabolite with established intranasal safety in clinical research, inadvertent high-dose intranasal self-exposure may produce nasal mucosal effects at non-physiological concentrations.
2. Handle the nasal spray solution in a clean laboratory environment under nitrogen or inert gas where possible. Minimize air exposure at each actuation. For aliquoting or analytical sampling, use a laminar flow cabinet.
3. The nasal spray solution is susceptible to both microbial contamination and oxidative degradation. Discard if the solution appears cloudy, discolored (yellow-brown discoloration indicates GSSG formation), or shows particulate matter, or after 7 days from first actuation, regardless of appearance.
4. Avoid aerosol generation during any manipulation of the nasal spray solution. Confirm the reduced form by Ellman’s reagent before each research use.

Exposure Risks

Risk Tier: LOW

Glutathione is an endogenous metabolite universally present in mammalian cells at millimolar concentrations and has one of the most favorable safety profiles of any compound in the RCDbio nasal spray research range. Clinical Phase I/IIa data specifically for the intranasal route confirm safety and tolerability in a PD patient population [Mischley et al., 2015; PMID 26230671]. The primary laboratory risk is inadvertent use of oxidized (GSSG-containing) material in redox-sensitive assay systems. Confirm the reduced form before each experimental use.

Storage

In-use nasal spray: Store at 2-8 degrees C. Use within 7 days of first actuation. Protect from light. Keep upright. Limit air exposure at actuation. Discard after 7 days regardless of remaining volume or appearance.

DO NOT FREEZE the ready-to-use nasal spray formulation. Freezing and thawing promote glutathione oxidation.

Lyophilized bulk stock: Store at -20 degrees C in sealed containers under inert gas (nitrogen or argon), desiccated, light-protected. Reseal immediately after each use under inert gas.

Discard any solution that appears cloudy, discolored (yellow-brown coloration), or shows visible particulate matter.

FAQs

Q: How does intranasal reduced glutathione access CNS targets, and why is this route preferred over oral in research?

A: Oral glutathione is degraded by gamma-glutamyl transpeptidase (GGT) in the intestinal brush border before reaching systemic circulation, resulting in very poor oral bioavailability. Intranasal delivery bypasses GI-tract GGT degradation and provides olfactory and trigeminal nerve-mediated nose-to-brain transport, directly elevating brain GSH levels. Phase I/IIa clinical data in PD patients support safety and tolerability at 300-600 mg/day [Mischley et al., 2015; PMID 26230671].

Q: What is the recommended storage and in-use shelf life for reduced glutathione nasal spray, and why is it shorter than other formulations?

A: Sealed product should be stored at 2-8 degrees C under an inert atmosphere, protected from light. Once first actuated, in-use shelf life is 7 days — substantially shorter than other single-peptide formulations (28 days), due to oxidative instability of the reduced thiol form in aqueous solution. DO NOT FREEZE. Minimize air exposure at actuation. Discard if yellow-brown discoloration is observed. Confirm the reduced form by Ellman’s reagent before research use.

Q: Is the reduced glutathione nasal spray formulation suitable for cell culture or in vitro assay systems?

A: The formulation is prepared in isotonic saline (0.9% NaCl, pH 5.0-6.5) without preservatives. The acidic pH is required for GSH stability but falls outside the typical cell culture pH range (7.2-7.4); dilution into culture medium before application to normalize pH is essential. Researchers must confirm the reduced form is intact by Ellman’s reagent assay before use in any redox-sensitive assay system. High GSH concentrations may induce protein glutathionylation in cell-free systems. Researchers are responsible for confirming compatibility.

Q: What is unique about reduced glutathione compared to other compounds in the RCDbio nasal spray range?

A: Reduced Glutathione has several unique characteristics: it is the only endogenous metabolite in the range universally present in all mammalian cells; it has the lowest molecular weight (~307 Da); it has a gamma-peptide bond rather than an alpha-peptide bond; it has direct antioxidant activity via free thiol without receptor mediation; it has a 7-day in-use shelf life due to oxidative instability; and it is the only compound in the entire RCDbio nasal spray range with published human Phase I/IIa clinical safety and tolerability data specifically for the intranasal route [Mischley et al., 2015; PMID 26230671].

Q: What is the WADA status of reduced glutathione?

A: Glutathione is not explicitly named on the 2026 WADA Prohibited List. As an endogenous antioxidant metabolite universally present in all mammalian cells, it does not fall within performance-enhancing substance categories at this time. Verify current status at GlobalDRO.com. RCDbio products are supplied for laboratory research purposes only.

Q: What is the FDA regulatory status of reduced glutathione?

A: Glutathione does not have a standalone FDA-approved pharmaceutical drug product for intranasal administration. RCDbio’s research-grade reduced glutathione nasal spray is not a pharmaceutical product, is not a dietary supplement, and is not equivalent to any approved or compounded glutathione formulation. It is supplied exclusively for in vitro and preclinical laboratory research purposes.

Q: Why does the reduced glutathione nasal spray solution need to be nitrogen-purged, and what happens if it oxidizes?

A: Reduced glutathione (GSH) is susceptible to oxidation to glutathione disulfide (GSSG; CAS 27025-41-8; MW 612.63 g/mol) in the presence of dissolved oxygen, particularly at physiological or alkaline pH. GSSG lacks the free thiol group responsible for antioxidant activity, GPx co-substrate function, and GST co-substrate activity. Nitrogen purging removes dissolved oxygen to slow this oxidation. Yellow-brown discoloration is an indicator of significant oxidation. Using oxidized material in place of GSH in redox-sensitive assay systems will produce incorrect results. Always confirm the reduced form by Ellman’s reagent (DTNB assay) before research use.

Related Research Compounds

Researchers investigating reduced glutathione nasal spray may also be interested in the following compounds currently available for laboratory research at RCDbio:

Epithalon Nasal Spray— A synthetic tetrapeptide investigated for telomerase modulation, neuroendocrine signaling, and direct cortical neuron activation via intranasal delivery; shares the CNS oxidative stress and neuroprotection research context.

BPC-157 Nasal Spray — A stable gastric pentadecapeptide investigated for NO-system modulation, cytoprotection, and endothelium protection in preclinical rodent preparations; complements reduced glutathione’s antioxidant research context via a non-overlapping cytoprotective mechanism.

MOTS-c Nasal Spray — A mitochondrial-derived peptide investigated for AMPK-mediated metabolic homeostasis and antioxidant response element (ARE) gene regulation; relevant as a complementary mitochondrial oxidative stress and cellular redox research tool.

All products listed are for laboratory and research purposes only.

References

1. Wu, G., Fang, Y.Z., Yang, S., Lupton, J.R., & Turner, N.D. (2004). Glutathione metabolism and its implications for health. The Journal of Nutrition, 134(3), 489-492.

   https://pubmed.ncbi.nlm.nih.gov/14988435/

2. Franco, R., Schoneveld, O.J., Pappa, A., & Panayiotidis, M.I. (2007). The central role of glutathione in the pathophysiology of human diseases. Archives of Physiology and Biochemistry, 113(4-5), 234-258.

   https://pubmed.ncbi.nlm.nih.gov/18158646/

3. Mischley, L.K., Leverenz, J.B., Lau, R.C., Polissar, N.L., Neradilek, M.B., Samii, A., & Standish, L.J. (2015). A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson’s disease. Movement Disorders, 30(12), 1696-1701.

   https://pubmed.ncbi.nlm.nih.gov/26230671/

4. Wong, C.Y.J., Baldelli, A., Hoyos, C.M., et al. (2024). Insulin delivery to the brain via the nasal route: unraveling the potential for Alzheimer’s Disease therapy. Drug Delivery and Translational Research, 14(7), 1776-1793.

   https://pubmed.ncbi.nlm.nih.gov/38441832/

Research Transparency Note: Reference 1 is a comprehensive biochemistry review of GSH metabolism. Reference 2 reviews the central pathophysiological role of GSH in human diseases. Reference 3 (Mischley et al., 2015; PMID 26230671) is a Phase I/IIa randomized double-blind clinical trial specifically investigating intranasal glutathione in 30 Parkinson’s disease patients — the only published human clinical trial of intranasal glutathione and the only compound-specific human intranasal clinical safety dataset in the entire RCDbio nasal spray research range; it establishes safety and tolerability only, not efficacy. Reference 4 provides class-level intranasal delivery evidence. Reduced Glutathione nasal spray is uniquely positioned in the RCDbio range as the only compound for which intranasal route-specific human clinical safety data is available.

Disclaimer

Reduced Glutathione (GSH) Nasal Spray is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition.

The Food and Drug Administration has not evaluated the statements on our website. This product is not approved for human or veterinary use. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@legacy.rcdbio.co